*Some restrictions apply. Visit http://www.glumetzaxr.com/glumetza-coupon-savings-program/ for details.
Salix Pharmaceuticals, Inc. reserves the right to modify or cancel these offerings at any time.
Indication for GLUMETZA:
GLUMETZA® (metformin hydrochloride extended-release tablets) is a prescription medicine that contains metformin hydrochloride used with diet and exercise to help control high blood sugar in adults with type 2 diabetes. GLUMETZA is not for people with type 1 diabetes. GLUMETZA is not for people with diabetic ketoacidosis (increased ketones in your blood or urine).
Important Safety Information about GLUMETZA
WARNING: LACTIC ACIDOSIS
Do not take GLUMETZA® (metformin hydrochloride extended-release tablets) if you:
Tell your healthcare provider if you drink alcohol very often, or drink a lot of alcohol in short-term.
Tell your healthcare provider if you are scheduled to have any tests that use radiocontrast or an injected dye or if you are having any surgical procedure that requires you to restrict your intake of food or liquids.
Your doctor should do blood tests to check how well your kidneys and liver are working before and during your treatment with GLUMETZA.
Tell your healthcare provider if you have problems with your liver. GLUMETZA may decrease your levels of Vitamin B12. Your doctor should monitor your blood levels on a yearly basis.
Tell your healthcare provider if you are taking insulin, or any of the following drugs as GLUMETZA may not be the right choice for you: amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin.
Safety and effectiveness in children younger than 18 years of age have not been established.
There have been no clinical studies that have been able to conclude a beneficial effect of GLUMETZA or any other oral anti-diabetic drug on reducing cardiovascular outcomes.
The most common adverse reactions (>5% of GLUMETZA-treated patients and at a rate greater than placebo) were low blood sugar (hypoglycemia). Symptoms of low blood sugar include: shaking, sweating, rapid heartbeat, change in vision, hunger, headache and change in mood. Other common adverse reactions include diarrhea, nausea, and upset stomach or stomach pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center
Please see complete Prescribing Information for GLUMETZA.
To the Patient: You must present this card to the pharmacist along with your prescription to participate in this program. If you have any questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the GLUMETZA® Instant Savings Card program at 877-264-2440 (8:00 AM-8:00 PM EST, Monday-Friday). When you use this card, you are certifying that you understand the program rules, regulations, and terms and conditions. You are not eligible if prescriptions are paid by any state or other federally funded programs, including, but not limited to Medicare or Medicaid, Medigap, VA or DOD, or TriCare, or where prohibited by law; and you will otherwise comply with the terms above.
Mail Order: The GLUMETZA Savings Card may be used for mail-order prescriptions.
Reimbursement: Benefits that were unable to be processed through mail-order may qualify for reimbursement. Please visit https://www.patientrebateonline.com/ for instructions on how to mail in your prescription receipt for reimbursement.
To the Pharmacist: When you use this card, you are certifying that you have not submitted and will not submit a claim for reimbursement under any federal, state, or other governmental programs for this prescription.
Salix reserves the right to modify or cancel these offerings at any time.
Please visit www.GLUMETZAXR.com for Full Prescribing Information including Patient Labeling.
Return this offer to patient for future use.
GLUMETZA® is a registered trademark of Valeant Pharmaceuticals International, Inc.
Santarus, Inc., is a wholly owned subsidiary of Salix Pharmaceuticals, Inc.
Links to all outside sites are provided as a resource to our visitors. Santarus accepts no responsibility for the content of sites that are not owned and operated by Santarus. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer.
Click "Continue" to proceed or "Return" to return to the GlumetzaXR.com website.